{"schema_version":"secwatch.filing_event.v1","accession":"0001339970-26-000027","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2026-05-11T20:03:51+00:00","discovered_at":"2026-05-11T20:05:00.609317+00:00","generated_at":"2026-05-11T22:54:48.499418+00:00","sec_items":["2.02","7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"confidence":"high","headline":"aTyr Pharma to launch new Phase 3 study of efzofitimod in pulmonary sarcoidosis after FDA feedback","bullets":["Cash, cash equivalents, and investments totaled $68.3M as of March 31, 2026 (unaudited).","FDA Type C meeting endorsed FVC as primary endpoint and KSQ-Lung as key secondary in new Phase 3.","New trial to enroll ~372 patients with restrictive lung disease (FVC ≤80% predicted) on stable corticosteroids.","Dosing changed to 5.0 mg/kg every 3 weeks (from every 4 weeks) with enhanced safety monitoring.","Company plans to submit IND for this Phase 3 study in June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001339970-26-000027","json":"https://secwatch.observer/filing/0001339970-26-000027.json","markdown":"https://secwatch.observer/filing/0001339970-26-000027.md","text":"https://secwatch.observer/filing/0001339970-26-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000027/0001339970-26-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000133997026000027/atyr-20260511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T22:54:48.499418+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}